Correlation Between Inhibrx and Compass Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Compass Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Compass Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Compass Therapeutics, you can compare the effects of market volatilities on Inhibrx and Compass Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Compass Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Compass Therapeutics.

Diversification Opportunities for Inhibrx and Compass Therapeutics

0.53
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Inhibrx and Compass is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Compass Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Compass Therapeutics and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Compass Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Compass Therapeutics has no effect on the direction of Inhibrx i.e., Inhibrx and Compass Therapeutics go up and down completely randomly.

Pair Corralation between Inhibrx and Compass Therapeutics

Given the investment horizon of 90 days Inhibrx is expected to generate 0.97 times more return on investment than Compass Therapeutics. However, Inhibrx is 1.03 times less risky than Compass Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Compass Therapeutics is currently generating about -0.03 per unit of risk. If you would invest  2,303  in Inhibrx on August 31, 2024 and sell it today you would lose (777.00) from holding Inhibrx or give up 33.74% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy99.79%
ValuesDaily Returns

Inhibrx  vs.  Compass Therapeutics

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Compass Therapeutics 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Compass Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Compass Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Inhibrx and Compass Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Compass Therapeutics

The main advantage of trading using opposite Inhibrx and Compass Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Compass Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compass Therapeutics will offset losses from the drop in Compass Therapeutics' long position.
The idea behind Inhibrx and Compass Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets